# **Key Findings**

# **PSORIASIS:** Journey to Stability

# **About Psoriasis**

125 million
(or 2-3% of the world's population)
has psoriasis

most common form
plaque
psoriasis
≈ 90% of patients



# 1 million Canadians have psoriasis

Up 30% have or will have arthritis

Mild

# <3% of the body.\*

Generally involves isolated patches on the knees, elbows, scalp, hands and feet.

Typically little effect on the quality of life.

\*To assess the area of involvement, consider that your palm covers about 1% of the skin's surface

#### **Moderate**

# **3-10**% of the body.\*

Generally appears on the arms, torso, scalp and other regions.

Often results in concern about others' reaction to visible lesions.

Generally affects thequality of life

#### Severe



>10% of the body.\*

May affect large areas of skin.
Psoriasis of the face and palms/
soles may be considered as
severe.

Typically has a severe impact on the quality of life.

# Respondents' Experiences on their Journey to Stability

286

survey responses from individuals living with or affected by psoriasis Of the respondents, approximately:



Majority of respondents have lived with psoriasis for

20+
years

Majority of respondents were in the age range of:

**51-65** years

# Top 5

### **Attributes Affected by Psoriasis**



**69%** Lack of self-esteem



58% Interrupted or loss of sleep



49% Anxiety



47% Depression



46% Avoid intimacy

#### **Reasons for Missed Work Days**

# Percentage 0 10 20 30 40 50 60 Depressed Didn't sleep Bleeding Too itchy Pain Joint stiffness Embarrassed (social stigma) Other

## **Description of Psoriasis**



#### Length of Time to Controlled/Stable



- 22% < 1 year</li>
   26% 2 10 years
   23% > 10 years
- 24% Still not controlled
  4% Can't recall
  3% Didn't answer
- What Needs to Change

- Reduce the length of time to access medications that control symptoms.
- 2 Expand educational outreach to health care professionals, patients, and loved ones.
- Develop educational resources, especially on treatment options, including biologics and biosimilars.
- 4 Support physicians' and patients' therapeutic choices.



